[1]李梦梦,张淑英,赵艳杰.视黄醇结合蛋白、胱抑素C、胃泌素前体释放肽水平联合超微血流成像在慢性肾脏病诊断中的价值研究[J].陕西医学杂志,2024,(4):483-486.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.010]
　LI Mengmeng,ZHANG Shuying,ZHAO Yanjie.Diagnostic value of RBP,CysC and proGRP in combination with superb micro-vascular imaging in chronic kidney disease[J].,2024,(4):483-486.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.010]
点击复制

视黄醇结合蛋白、胱抑素C、胃泌素前体释放肽水平联合超微血流成像在慢性肾脏病诊断中的价值研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年4期
页码:
483-486
栏目:
临床研究
出版日期:
2024-04-05

文章信息/Info

Title:
Diagnostic value of RBP,CysC and proGRP in combination with superb micro-vascular imaging in chronic kidney disease
作者:
李梦梦; 张淑英; 赵艳杰
(苏州大学附属第二医院超声科,江苏 苏州 215000)
Author(s):
LI Mengmeng; ZHANG Shuying; ZHAO Yanjie
(Department of Ultrasound,the Second Affiliated Hospital of Soochow University,Suzhou 215000,China)
关键词:
慢性肾脏病;  视黄醇结合蛋白;  胱抑素C;  胃泌素前体释放肽;  超微血流成像;  诊断价值
Keywords:
Chronic kidney disease;  Retinol-binding protein;  Cystatin C;  Gastrin precursor releasing peptide;  Superb micro-vascular imaging;  Diagnostic value
分类号:
R 697
DOI:
DOI:10.3969/j.issn.1000-7377.2024.04.010
文献标志码:
A
摘要:
目的:研究视黄醇结合蛋白(RBP)、胱抑素C(CysC)、胃泌素前体释放肽(proGRP)水平联合超微血流成像(SMI)对慢性肾脏病的诊断价值。方法:选择175例收治的慢性肾脏病患者和183例健康体检者分别作为病例组和健康对照组,统计两组血清RBP、CysC、proGRP水平及SMI评分,采用受试者工作特征曲线(ROC)分析血清RBP、CysC、proGRP及SMI评分对慢性肾脏病的诊断价值; 根据慢性肾脏病患者分期将其分为1、2、3、4、5期组,分别为28例、31例、36例、38例、42例,比较不同分期慢性肾脏病患者血清RBP、CysC、proGRP水平及SMI评分。结果: 病例组血清RBP、CysC、proGRP水平高于健康对照组,SMI评分低于健康对照组(均P<0.05)。血清RBP、CysC、proGRP及SMI评分联合诊断慢性肾脏病的曲线下面积(AUC)及敏感度高于四者单独检测(均P<0.05)。3、4、5期组血清RBP水平高于1、2期组,3、4、5期组血清RBP水平呈升高趋势(均P<0.05); 1、2、3、4、5期组血清CysC、proGRP水平呈升高趋势,SMI评分呈降低趋势(均P<0.05)。结论: 血清RBP、CysC、proGRP及SMI评分联合可有效提高对慢性肾脏病的诊断价值,且四者水平变化与慢性肾脏病患者分期密切相关。
Abstract:
Objective: To study the diagnostic value of retinol-binding protein(RBP),cystatin C(CysC)and gastrin protoxin-releasing peptide(proGRP)in combination with superb micro-vascular imaging(SMI)in chronic kidney disease.Methods:175 patients with chronic kidney disease and 183 healthy subjects who underwent physical examination were selected as the case group and the control group,respectively.Serum levels of RBP,CysC and proGRP and score of SMI of the two groups were analyzed.The diagnostic value of serum RBP,CysC,proGRP and score of SMI in chronic kidney disease was analyzed by ROC curve.According to the stages of chronic kidney disease,the patients were divided into stage 1,2,3,4 and 5 groups,with 28 cases,31 cases,36 cases,38 cases and 42 cases,respectively.The serum levels of RBP,CysC,proGRP and SMI score of patients with different stages of chronic kidney disease were compared.Results:The serum levels of RBP,CysC and proGRP in the case group were higher than those in the healthy control group,and the score of SMI was lower than that in the healthy control group(all P<0.05).The AUC and sensitivity of serum RBP,CysC,proGRP and score of SMI combined with the diagnosis of chronic kidney disease were higher than those of the four alone(all P<0.05).The serum level of RBP in stage 3,4 and 5 groups was higher than that in stage 1 and 2 groups,and the serum level of RBP in stage 3,4 and 5 groups showed an increasing trend(all P<0.05).The serum levels of CysC and proGRP in stage 1,2,3,4 and 5 groups increased,and the score of SMI decreased(all P<0.05).Conclusion:The combination of serum RBP,CysC,proGRP and score of SMI could effectively improve the diagnostic value of chronic kidney disease,and the changes of the levels of four were closely related to the stage of chronic kidney disease patients.

参考文献/References:

[1] YANAI H,ADACHI H,HAKOSHIMA M,et al.Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome,cardiovascular diseases and chronic kidney disease[J].Int J Mol Sci,2021,22(17):9221.
[2] SMYTH B,GLASER J,BUTLER-DAWSON J,et al.Challenges and opportunities in interventions for chronic kidney disease of unknown origin(CKDu):Report from the international society of nephrology consortium of collaborators on CKDu[J].Kidney Int,2023,103(1):6-12.
[3] IOLASCON G,MORETTI A.What are the efficacy and safety of pharmacological interventions versus placebo,no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5-A cochrane review summary with commentary[J].J Musculoskelet Neuronal Interact,2022,22(1):1-4.
[4] 董丽娟,牛奔,马丽,等.尿MCP-1、KIM-1及血清CysC用于2型糖尿病相关肾病的临床诊断价值[J].河北医药,2019,41(1):37-41.
[5] 唐江利,张华,陈海丹,等.血清CHE、Alb、RBP表达水平联合检测在小儿原发性肾病综合征早期筛查中的应用价值分析[J].中国中西医结合肾病杂志,2021,22(9):792-793.
[6] 胡晓莉,明志强,屈茜萍,等.超微血流成像与CDFI评估慢性肾脏病患者血流灌注的对比研究[J].临床超声医学杂志,2022,24(5):393-396.
[7] 王海燕.肾脏病学[M].北京:人民卫生出版社,2008:112-115.
[8] 梁红敏,陆永萍,陈敏,等.超微血流与彩色多普勒半定量分析在慢性肾脏病肾血流灌注中的应用[J].昆明医科大学学报,2021,42(2):38-42.
[9] 余清,滕凤猛.不同分期慢性肾脏疾病患者血清检测指标对其治疗和预后临床价值的探讨[J].南京师大学报(自然科学版),2021,44(1):99-103.
[10] 王萍,王文娟,杜翔.慢性肾脏病患者肾素-血管紧张素系统与血浆β-淀粉样蛋白相关性研究[J].陕西医学杂志,2022,51(5):574-577,590.
[11] 齐宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,43(5):596-599.
[12] MASAJTIS-ZAGAJEWSKA A,MURAS K,NOWICKI M.Effects of a structured physical activity program on habitual physical activity and body composition in patients with chronic kidney disease and in kidney transplant recipients[J].Exp Clin Transplant,2019,17(2):155-164.
[13] 马蕾媛,杨雪,郑曙光,等.彩色多普勒感兴趣区定量技术评价慢性肾脏病患者肾脏末梢血流灌注的临床价值[J].临床超声医学杂志,2022,24(4):281-285.
[14] 何建忠,陈光权.高通量血液透析对2型糖尿病肾病患者毒素清除和炎症因子、氧化应激因子水平的影响[J].标记免疫分析与临床,2019,26(4):571-575.
[15] 舒银珍,全晖,曾志荣,等.血清淀粉样蛋白A视黄醇结合蛋白和尿β2微球蛋白在妊娠期高血压疾病早期肾损伤中的诊断价值[J].河北医学,2022,28(1):66-71.
[16] 朱清,高勇.外周血RBP与β2M联合检测对2-4期慢性肾脏病并发急性肾损伤的预警价值[J].中南医学科学杂志,2023,51(2):281-284.
[17] 张静洁,石雨申,张艳霞.血清趋化素、脂联素、胱抑素C及FGF23预测慢性肾脏病4-5期患者血液透析后钙磷代谢紊乱的价值[J].武警医学,2022,33(2):129-133.
[18] 李友河,薛志强,曾石养,等.联合检查血清抗PLA2R、CysC和TNF对特发性膜性肾病患者的预后价值研究[J].河北医药,2020,42(14):2121-2124.
[19] 戴健敏,陈诺,魏坚.慢性肾脏病不同阶段患者血清ProGRP、NSE、CYFRA21-1水平的变化[J].检验医学,2022,37(9):811-814.
[20] 陆明洋,徐斌,李敏,等.慢性肾脏病对血清胃泌素释放肽前体测定的影响[J].标记免疫分析与临床,2019,26(9):1524-1527.
[21] 梁红敏,陆永萍,陈敏,等.超微血流与彩色多普勒半定量分析在慢性肾脏病肾血流灌注中的应用[J].昆明医科大学学报,2021,42(2):38-42.
[22] 胡晓莉,明志强,顾鹏,等.超微血流成像与CDFI在慢性肾脏病肾血流灌注中的应用[J].西部医学,2023,35(2):298-302.
[23] 施秀荣,张渊,单君,等.超微血管成像及超声造影技术评价慢性肾功能不全患者颈动脉粥样硬化斑块稳定性的研究[J].影像科学与光化学,2021,39(1):87-90.
[24] 许莹,周瑜,李丽娜,等.超微血管显像联合增强CT诊断直径<3 cm肾脏肿瘤的价值[J].临床超声医学杂志,2021,23(12):951-954.
[25] 姚俊东,刘彬彬,王运昌,等.超微血流成像联合声脉冲辐射力弹性成像对IgA肾病的诊断价值[J].新乡医学院学报,2022,39(7):637-641.

相似文献/References:

[1]杨 雄,高 伟,邱万胜,等.白蛋白球蛋白比值对慢性肾脏病患者预后判断的价值研究[J].陕西医学杂志,2020,49(6):728.[doi:DOI:10.3969/j.issn.10007377.2020.06.022]
[2]蒋晓颖,赵雪卉,张 娟.妊娠高血压早期肾损伤情况及其与血清视黄醇结合蛋白、尿酸关系研究[J].陕西医学杂志,2021,50(2):151.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.006]
　JIANG Xiaoying,ZHAO Xuehui,ZHANG Juan.Early renal injury in gestational hypertension and its relationship with serum sRBP and UA[J].,2021,50(4):151.[doi:DOI:10.3969/j.issn.1000-7377.2021.02.006]
[3]王 萍,王文娟,杜 翔.慢性肾脏病患者肾素-血管紧张素系统与血浆β-淀粉样蛋白相关性研究[J].陕西医学杂志,2022,51(5):574.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.014]
　WANG Ping,WANG Wenjuan,DU Xiang.Correlation between renin-angiotensin system and plasma beta-amyloid peptide in patients with chronic kidney disease and its significance[J].,2022,51(4):574.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.014]
[4]方修移,吴小冬,潘美娟,等.罗沙司他治疗慢性肾脏病合并肾性贫血临床价值研究[J].陕西医学杂志,2024,(5):666.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.020]
　FANG Xiuyi,WU Xiaodong,PAN Meijuan,et al.Value of roxadustat in the treatment of chronic kidney disease complicated with renal anemia[J].,2024,(4):666.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.020]

备注/Memo

备注/Memo:
基金项目:省部共建放射医学与辐射防护国家重点实验室开放课题(GZK1202206)
更新日期/Last Update: 2024-04-07